How to access Entresto from Saudi Arabia, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A Saudi Arabia patient with heart failure with reduced ejection fraction (HFrEF), or, per newer labeling, chronic heart failure across the ejection-fraction spectrum, may receive a prescription for Entresto (sacubitril/valsartan) from their treating cardiologist or heart-failure specialist. Entresto is FDA-approved for heart failure and developed by Novartis. Entresto is registered in parts of Saudi Arabia supply chain, but formulary coverage varies by institution and specific strength, this guide addresses access when your prescribing hospital's formulary does not reliably stock Entresto at the required titration strength or when a supply gap has emerged.
This guide explains the pathway, documentation your physician prepares, typical timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Entresto is an oral angiotensin receptor-neprilysin inhibitor (ARNI) combining sacubitril and valsartan, dosed twice daily with titration from 24/26 mg through 49/51 mg to 97/103 mg based on tolerability and blood pressure. Eligibility anchors to symptomatic heart failure, appropriate wash-out from ACE inhibitors (at least 36 hours to avoid angio-oedema risk), adequate blood pressure, and renal/potassium monitoring. Your cardiologist sets the titration schedule and follow-up cadence.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Is Entresto legally importable into Saudi Arabia?
Yes, via the Saudi Food and Drug Authority (SFDA) named-patient / special-access import framework when Entresto is not reliably stocked at your prescribing institution, when the specific titration strength is out of supply, or when there is a documented formulary gap.
The mechanism permits a KSA-licensed physician to import a medicine not routinely available at the institution when (a) the medicine is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent alternative is suitable and available at that institution, (c) the physician accepts clinical responsibility, and (d) chain of custody is documented.
How the pathway works, step by step
- Consultation with your treating cardiologist. HFrEF / HF documentation, wash-out plan from ACE inhibitors, current titration history, and clinical rationale.
- Baseline assessment. NYHA class, ejection fraction, NT-proBNP, blood pressure trajectory, renal panel, potassium.
- SFDA named-patient application. The physician or hospital pharmacy files clinical rationale (including formulary-gap note where relevant), patient reference, titration strengths, and dosing schedule.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Entresto from authorised distribution under DSCSA.
- Ambient shipment. Entresto ships under controlled ambient conditions with chain-of-custody documentation.
- Arrival and dispensing. The hospital pharmacy releases the bottle to the patient with the titration schedule.
What documentation your physician needs
- Clinical rationale letter confirming heart failure indication and Entresto as the indicated therapy
- Verification of Saudi Arabia medical license (SCFHS)
- NYHA class, ejection-fraction report, NT-proBNP
- ACE-inhibitor wash-out plan documentation
- Baseline renal panel and potassium
- Planned titration schedule through target dose
Reserve Meds provides a physician documentation kit bundling templates SFDA reviewers expect for heart-failure named-patient imports.
Costs and timing
Entresto's US cash-pay drug-only reference cost sits in an indicative 2026 annual range of roughly USD 7,500-8,500 at maintained titration. International logistics, SFDA documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a transparent quote at the start of intake. Indicative range.
Indicative timing for first dispense after cohort intake opens is 7-14 days from the moment a complete SFDA application is submitted.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
Reserve Meds's role
- Sourcing. Through our US-licensed specialty wholesale partner under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and SFDA review.
- Logistics. Ambient-controlled shipment to your prescribing hospital.
- Concierge case lead. A named point of contact coordinating titration-phase and maintenance refills.
What we do not do: We are not the prescriber, do not practise medicine, and are not the dispensing pharmacy. All clinical decisions remain with your treating cardiologist.
Frequently asked
My hospital already stocks Entresto, do I need this pathway? No. Use the local pathway where reliably available. Reserve Meds steps in only where there is a documented formulary or supply gap.
How is Entresto different from ACE inhibitors or ARBs alone? Entresto pairs an ARB (valsartan) with a neprilysin inhibitor (sacubitril). The combined mechanism demonstrated outcomes benefit in the PARADIGM-HF trial. Your cardiologist will make the selection.
What is the angio-oedema risk? Entresto must not be combined with ACE inhibitors; a 36-hour wash-out is required when switching. History of ACE-inhibitor-related angio-oedema is a contraindication.
Will insurance cover this? Cash-pay is the default for named-patient imports. Some Saudi Arabia private insurers consider case by case; we supply documentation but do not process claims directly.
Next step
Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. We are not a pharmacy, not the prescriber, and not the manufacturer. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.
Clinical & regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-04-23.
Regulatory status of Entresto (sacubitril/valsartan) in Saudi Arabia, 2026
Entresto (sacubitril/valsartan) is approved by the US Food and Drug Administration for the labelled indication of chronic heart failure (reduces risk of cardiovascular death and hospitalisation) in adults and paediatric heart failure (see the FDA approval record at accessdata.fda.gov). The European Medicines Agency holds a parallel marketing authorisation where applicable (see the EMA EPAR at ema.europa.eu). For a Saudi Arabia-based patient, the access pathway runs through the Saudi Food and Drug Authority (SFDA) framework. The official regulator portal is at www.sfda.gov.sa/en; the locally registered medicines list is at www.sfda.gov.sa/en/drugs-list.
Where Entresto (sacubitril/valsartan) is held on the locally registered list at the time the case opens, standard prescription and in-country dispensing applies and the treating consultant at the prescribing tertiary centre coordinates supply through the institutional pharmacy. Where Entresto (sacubitril/valsartan) is not yet on the locally registered list at the time the case opens, the named-patient and personal-import framework that the Saudi Food and Drug Authority (SFDA) maintains for reference-authority-approved medicines is the operative route. The qualifying conditions are well established: the medicine is approved by a recognised reference authority (FDA or EMA qualifies), no locally available alternative is clinically equivalent for the specific patient indication, the treating physician of record takes documented clinical responsibility, and chain of custody is preserved end to end from the US source through international transit to the named dispensing facility. Confirm current registration status at intake; the published registration list governs.
Tertiary centers and clinical coordination in Saudi Arabia
The Saudi Arabia tertiary referral network for a Entresto (sacubitril/valsartan) case is concentrated at King Faisal Specialist Hospital and Research Centre (KFSHRC) Riyadh and Jeddah, King Abdulaziz Medical City (KAMC), King Fahad Medical City (KFMC), Princess Noorah Oncology Center, and King Fahd Specialist Hospital Dammam. These centers carry the haematology, oncology, neurology, metabolic, infectious-disease, or rare-disease specialist staffing and the institutional pharmacy and import-license operations that the named-patient pathway requires. For angiotensin receptor-neprilysin inhibitor (ARNI) therapies that require specialised infusion infrastructure, baseline organ-function workup, or post-treatment monitoring of a complexity beyond what a community centre is configured for, the case is routinely referred to one of these tertiary centers from the outset.
For oral, subcutaneous, or in-clinic infusion therapies that can be administered in Saudi Arabia once imported, the tertiary centres dispense and monitor under their institutional pharmacy operations. Reserve Meds handles US-side sourcing under Drug Supply Chain Security Act (DSCSA) chain-of-custody documentation, international shipment to the named dispensing facility, and re-supply cadence aligned to the dosing schedule. For therapies that require US-certified treatment center administration (some cell, gene, and complex biologics fall in this bucket), the practical access pathway runs through patient travel to a US-certified treatment center rather than import into Saudi Arabia; the Saudi Arabia tertiary team continues to handle upstream referral package assembly and the long-term follow-up after the patient returns home.
Saudi Arabia pricing reference and payer posture, 2026
Reserve Meds publishes a drug-only US cash-pay reference range at intake and issues a delivered, itemised quote within 24 hours once the treating physician's documentation is in. The 2026 reference rate used for SAR conversion is 1 USD = 3.750 SAR. As an illustrative composite case in the 2026 reference band, the US cash-pay drug-only cost for Entresto (sacubitril/valsartan) reflects the US wholesale acquisition cost published by the manufacturer (Novartis) plus standard specialty pharmacy markup; the precise band is delivered in the case quote because it varies by indication, dosing, and pack size.
Logistics, international shipment, chain-of-custody documentation, cold-chain handling where applicable, Reserve Meds concierge coordination, and any patient and caregiver travel and accommodation are itemised separately. For a complex case the total course cost commonly lands meaningfully above the drug-only band once treatment-centre fees, pre-treatment workup, on-treatment monitoring, complication management, and family logistics are added in.
Payer posture in Saudi Arabia is overwhelmingly cash-pay for named-patient imports and cross-border specialty cases. The relevant public-payer body is CCHI (Council of Cooperative Health Insurance); the portal is at www.cchi.gov.sa. Public coverage generally does not extend to non-locally-registered specialty cases. Private health insurance plans review case-by-case on a pre-authorisation basis when the documentation package is strong, but cash-pay should be assumed as the default at intake.
Access barriers and how Reserve Meds clears them
The five access barriers we see most often for a Entresto (sacubitril/valsartan) case in Saudi Arabia are: (1) Regulatory documentation complexity. The Saudi Food and Drug Authority (SFDA) named-patient and personal-import application package requires a specific bundle (physician clinical rationale letter, prescription, patient identifier, product strength and quantity, chain-of-custody plan, evidence of reference-authority approval, and confirmation that no locally available alternative is clinically equivalent for the patient). Reserve Meds provides physician-facing templates that match the format reviewers expect. (2) US-side sourcing and DSCSA chain-of-custody. We coordinate with our US-licensed specialty wholesale partners to secure Entresto (sacubitril/valsartan) from authorised distribution under the US Drug Supply Chain Security Act, logging every transfer point through to international shipment.
(3) Clinical eligibility documentation. The treating consultant at the prescribing tertiary centre defines eligibility against the FDA labelled indication and the relevant clinical-practice guideline; Reserve Meds does not adjudicate the clinical decision. (4) Family logistics. Patient and caregiver travel where applicable, accommodation near the treatment center where applicable, in-country transport, translator support where needed, and post-treatment data flow back to the treating Saudi Arabia physician are coordinated as a single arc. (5) Insurance and payer posture. Cash-pay is the default. Where private insurance review is contemplated, we supply documentation for the family's submission but we do not bill insurers and we do not adjudicate insurance disputes.
Drug-specific clinical context for Entresto (sacubitril/valsartan): the labelled indication is chronic heart failure (reduces risk of cardiovascular death and hospitalisation) in adults and paediatric heart failure. The angiotensin receptor-neprilysin inhibitor (ARNI) mechanism shapes both the eligibility workup and the monitoring schedule. The relevant clinical-practice guideline body is American Heart Association (AHA), American College of Cardiology (ACC), and European Society of Cardiology (ESC) heart failure guidelines at www.escardio.org/Guidelines. The treating physician of record makes the clinical decision; Reserve Meds is the coordination layer that clears the operational and regulatory barriers between the prescription and the delivered course.
Recent regulatory and access news for Entresto (sacubitril/valsartan) in Saudi Arabia, 2026
The Saudi Food and Drug Authority (SFDA) portal at www.sfda.gov.sa/en and the locally registered medicines list at www.sfda.gov.sa/en/drugs-list are the authoritative source for the current Saudi Arabia listing status of Entresto (sacubitril/valsartan); the snapshot date governs. The FDA Drug Safety Communications feed at fda.gov drug-safety-communications and the FDA Drug Shortages list at accessdata.fda.gov drugshortages are the authoritative sources for any active Entresto (sacubitril/valsartan) safety advisory or shortage signal over the most recent 12-month window. The FDA labelled indication for Entresto (sacubitril/valsartan) remains chronic heart failure (reduces risk of cardiovascular death and hospitalisation) in adults and paediatric heart failure (see the current FDA approval record at accessdata.fda.gov). Novartis continues commercial supply per the FDA-labelled indication and the EMA marketing authorisation. The American Heart Association (AHA), American College of Cardiology (ACC), and European Society of Cardiology (ESC) heart failure guidelines guidance at www.escardio.org/Guidelines remains the relevant clinical-practice reference. Reserve Meds refreshes this snapshot per case at intake; the snapshot date governs.